Conditioning Therapy Options: Fludarabine and Melphalan for Older Adults with AML and MDS

Research has shown that using fludarabine and melphalan as a conditioning regimen improves outcomes for older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 

A conditioning regimen is a treatment that prepares a person for a stem cell transplant. The regimen can consist of chemotherapy, a monoclonal antibody, or radiation. During this process, the conditioning regimen makes space in the bone marrow for new stem cells, prevents potential rejection of transplanted cells, and also destroys cancer cells that are in the body. Because of the intensity and serious side effects that come with many conditioning regimens, they can be difficult for older adults and people with other health conditions to tolerate.  

Reduced intensity conditioning regimens are treatments that use less chemotherapy and radiation than standard regimens. They can help to reduce the risks associated with stem cell transplants. 

There are several different reduced intensity conditioning regimens that are regularly used, but researchers wanted to understand which regimen produced the best results. In a recent study, researchers looked at patients 50 years and older who had received a reduced-intensity conditioning regimen between 2013 and 2022. 

They looked at patients who had received fludarabine-based regimens, including:

FM100 or FM140: fludarabine and two different levels of doses of melphalan-100 mg and 140 mg.

FB2: fludarabine with 2 days of busulfan

FCT: fludarabine and cyclophosphamide

• FT: fludarabine and total body irradiation

People who received fludarabine and melphalan had the best outcomes overall

The study found that the FM100 treatment combination of fludarabine and melphalan resulted in the best outcomes. Overall survival (OS) was highest among patients who received this conditioning regimen (53%). OS is how long a person survives after treatment begins.  

OS among other groups was:

• 48% for FB2 
• 47% for FCT 
• 38% for FT

Disease-free survival (DFS) was also significantly higher for people who received FM100 or FM140 when compared to people who received FCT and FT. DFS is the amount of time after treatment begins that the cancer does not grow or change. 

This research shows that people with AML and MDS undergoing stem cell transplant who received a conditioning regimen of fludarabine and melphalan had better outcomes related to survival.

Selecting the right conditioning therapy is a very individual process that depends on factors such as overall health, genetic features, and disease risk. Your care team will weigh each of these factors when determining the best option for you.  

Your health data all in one place with HealthTree 

When you connect your medical records to HealthTree, all of your health data is in one place. It can help you monitor your labs, see out-of-range values, and learn what has worked for others with your same disease. This is a safe, secure way to take control of your health data. Sign up for your free account today! 

Join Cure Hub Today!

Sources: 

•  Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation 
• Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?